Literature DB >> 15795922

Primary plasma cell leukemia: report of 17 new cases treated with autologous or allogeneic stem-cell transplantation and review of the literature.

Steven Saccaro1, Rafael Fonseca, Diana M Veillon, James Cotelingam, Mary L Nordberg, Christopher Bredeson, Jonathan Glass, Reinhold Munker.   

Abstract

Primary plasma cell leukemia (PPCL) is a rare hematologic malignancy characterized by the proliferation of plasma cells in blood, bone marrow, and other organs in the absence of established multiple myeloma. PPCL has a poor prognosis when treated with conventional therapy for multiple myeloma. We describe here 17 new cases of PPCL who underwent stem-cell transplantation (SCT) (2 cases observed by the authors and 15 cases from the International Bone Marrow Transplant Registry [IBMTR]). The first case was diagnosed in a 21-year-old male who presented with leukocytosis and acute renal failure. He was treated with hyper-CVAD, entered complete remission, and then proceeded to high-dose chemotherapy with peripheral stem-cell support. He is currently in complete remission 23 months after initial diagnosis and 19 months after autologous SCT. The second case was observed in a 31-year-old male who presented with leukocytosis and hepatic infiltration with plasma cells. He was treated with VAD chemotherapy and underwent allogeneic bone marrow transplantation from his HLA-identical sister. He remained in complete remission for 3 years and then developed progressive refractory disease, dying 7 years after the initial diagnosis. In addition to these 2 cases, 15 further unpublished cases of PPCL from the IBMTR are reported here (treated between 1993 and 2001, 6 by autologous and 9 by allogeneic transplantation). Finally, the features of PPCL, the outcome, published data of SCT for PPCL, and indications for treatment are discussed.

Entities:  

Mesh:

Year:  2005        PMID: 15795922     DOI: 10.1002/ajh.20272

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  14 in total

1.  Plasma cell leukemia.

Authors:  Moria A Gertz; Francis K Buadi
Journal:  Haematologica       Date:  2010-05       Impact factor: 9.941

2.  Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia.

Authors:  P Musto; V Simeon; M C Martorelli; M T Petrucci; N Cascavilla; F Di Raimondo; T Caravita; F Morabito; M Offidani; A Olivieri; G Benevolo; R Mina; R Guariglia; G D'Arena; G Mansueto; N Filardi; F Nobile; A Levi; A Falcone; M Cavalli; G Pietrantuono; O Villani; S Bringhen; P Omedè; R Lerose; L Agnelli; K Todoerti; A Neri; M Boccadoro; A Palumbo
Journal:  Leukemia       Date:  2013-08-20       Impact factor: 11.528

Review 3.  How I treat plasma cell leukemia.

Authors:  Niels W C J van de Donk; Henk M Lokhorst; Kenneth C Anderson; Paul G Richardson
Journal:  Blood       Date:  2012-07-26       Impact factor: 22.113

Review 4.  Plasma cell leukaemia and other aggressive plasma cell malignancies.

Authors:  Taimur Sher; Kena C Miller; George Deeb; Kelvin Lee; Asher Chanan-Khan
Journal:  Br J Haematol       Date:  2010-08       Impact factor: 6.998

Review 5.  Plasma cell leukemia.

Authors:  Flavio Albarracin; Rafael Fonseca
Journal:  Blood Rev       Date:  2011-02-03       Impact factor: 8.250

Review 6.  Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group.

Authors:  C Fernández de Larrea; R A Kyle; B G M Durie; H Ludwig; S Usmani; D H Vesole; R Hajek; J F San Miguel; O Sezer; P Sonneveld; S K Kumar; A Mahindra; R Comenzo; A Palumbo; A Mazumber; K C Anderson; P G Richardson; A Z Badros; J Caers; M Cavo; X LeLeu; M A Dimopoulos; C S Chim; R Schots; A Noeul; D Fantl; U-H Mellqvist; O Landgren; A Chanan-Khan; P Moreau; R Fonseca; G Merlini; J J Lahuerta; J Bladé; R Z Orlowski; J J Shah
Journal:  Leukemia       Date:  2012-11-21       Impact factor: 11.528

Review 7.  Primary Plasma Cell Leukemia: Identity Card 2016.

Authors:  Pellegrino Musto; Vittorio Simeon; Katia Todoerti; Antonino Neri
Journal:  Curr Treat Options Oncol       Date:  2016-04

Review 8.  Plasma cell leukemia: a highly aggressive monoclonal gammopathy with a very poor prognosis.

Authors:  Victor H Jimenez-Zepeda; Virginia J Dominguez-Martinez
Journal:  Int J Hematol       Date:  2009-03-27       Impact factor: 2.490

9.  A Rare Case of Primary Plasma Cell Leukaemia with Monosomy X.

Authors:  Smita Surendra Masamatti; Aparna Narasimha; Archana C Shetty; C Vijaya
Journal:  J Clin Diagn Res       Date:  2017-08-01

10.  Lenalidomide, melphalan, and prednisone association is an effective salvage therapy in relapsed plasma cell leukaemia.

Authors:  Tommasina Guglielmelli; Roberta Merlini; Emilia Giugliano; Giuseppe Saglio
Journal:  J Oncol       Date:  2009       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.